Correlation Between Eliem Therapeutics and Nuvectis Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and Nuvectis Pharma, you can compare the effects of market volatilities on Eliem Therapeutics and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Nuvectis Pharma.

Diversification Opportunities for Eliem Therapeutics and Nuvectis Pharma

-0.07
  Correlation Coefficient

Good diversification

The 3 months correlation between Eliem and Nuvectis is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Nuvectis Pharma go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Nuvectis Pharma

Given the investment horizon of 90 days Eliem Therapeutics is expected to generate 1.19 times more return on investment than Nuvectis Pharma. However, Eliem Therapeutics is 1.19 times more volatile than Nuvectis Pharma. It trades about 0.04 of its potential returns per unit of risk. Nuvectis Pharma is currently generating about 0.0 per unit of risk. If you would invest  251.00  in Eliem Therapeutics on September 2, 2024 and sell it today you would earn a total of  53.00  from holding Eliem Therapeutics or generate 21.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy99.19%
ValuesDaily Returns

Eliem Therapeutics  vs.  Nuvectis Pharma

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Nuvectis Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Nuvectis Pharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Eliem Therapeutics and Nuvectis Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and Nuvectis Pharma

The main advantage of trading using opposite Eliem Therapeutics and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.
The idea behind Eliem Therapeutics and Nuvectis Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Commodity Directory
Find actively traded commodities issued by global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories